172734-70-2

Basic information

• Product Name: Methanone, [(3S)-3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)-1-piperidinyl]phenyl-
• Synonyms: Methanone, [(3S)-3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)-1-piperidinyl]phenyl-;(S)-(3-(3,4-Dichlorophenyl)-3-(3-hydroxypropyl)piperidin-1-yl)(phenyl)methanone
• CAS NO: 172734-70-2
• Molecular Formula: C₂₁H₂₃Cl₂NO₂
• Molecular Weight: 392.31882
• Mol File: 172734-70-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methanone, [(3S)-3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)-1-piperidinyl]phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, [(3S)-3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)-1-piperidinyl]phenyl-(172734-70-2)
• EPA Substance Registry System: Methanone, [(3S)-3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)-1-piperidinyl]phenyl-(172734-70-2)

Safety Data

• Hazardous Substances Data: 172734-70-2(Hazardous Substances Data)

Upstream product

• 193755-91-8 3(S)-3-(3,4-Dichlorophenyl)-3-allylpiperidine 
• 98-88-4 benzoyl chloride 

Downstream Products

• 172734-92-8 osanetant 
• 188916-67-8 [(S)-3-(3,4-Dichloro-phenyl)-3-(3-iodo-propyl)-piperidin-1-yl]-phenyl-methanone 
• 172734-71-3 (+)-3(S)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-(3-methanesulphonyloxypropyl)piperidine 

Relevant articles and documents

Construction of Quaternary Carbon Center by Catalytic Asymmetric Alkylation of 3-Arylpiperidin-2-ones Under Phase-Transfer Conditions

A highly enantioselective synthesis of δ-lactams having a chiral quaternary carbon center at the α-position has been developed through an asymmetric alkylation of 3-arylpiperidin-2-ones under phase-transfer conditions. In this transformation, a 2,2-diarylvinyl group on the δ-lactam nitrogen atom plays a crucial role as a novel protecting group and an achiral auxiliary for improving both yield and enantioselectivity of the reaction.

Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Compounds of the formula (I): where X1, A, Ar1, X and R are as defined in the specification, and pharmaceutically-acceptable salts thereof, are new, and are useful as tachykinin inhibitors which act at the NK1, NK2and NK3receptors or a combination of two or more thereof.